# Wai Tong Ng

#### List of Publications by Citations

Source: https://exaly.com/author-pdf/811672/wai-tong-ng-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137
papers

5,829
citations

40
p-index

75
g-index

7,046
ext. papers

7,046
ext. citations

4.3
avg, IF

L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 137 | Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 645-55  | 21.7 | 453       |
| 136 | Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3356-64   | 2.2  | 410       |
| 135 | Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 118  | 898  | 250       |
| 134 | Current management of nasopharyngeal cancer. Seminars in Radiation Oncology, 2012, 22, 233-44  | 5.5  | 241       |
| 133 | Evolution of treatment for nasopharyngeal cancersuccess and setback in the intensity-modulated radiotherapy era. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 110, 377-84  | 5.3  | 216       |
| 132 | Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 420-8  | 4    | 209       |
| 131 | What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 498-505   | 2.2  | 176       |
| 130 | The battle against nasopharyngeal cancer. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 272-8  | 5.3  | 166       |
| 129 | Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , <b>2016</b> , 122, 546-58   | 6.4  | 164       |
| 128 | COVID-19 pandemic: Effects and evidence-based recommendations for otolaryngology and head and neck surgery practice. <i>Head and Neck</i> , <b>2020</b> , 42, 1259-1267  | 4.2  | 159       |
| 127 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer. <i>Investigational New Drugs</i> , <b>2011</b> , 29, 1449-58   | 4.3  | 157       |
| 126 | Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 656-66   | 7.5  | 154       |
| 125 | Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients | 6.4  | 130       |
| 124 | Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). <i>Oral Oncology</i> , <b>2018</b> , 77, 16-21  | 4.4  | 112       |
| 123 | Whole-exome sequencing identifies multiple loss-of-function mutations of NF- <b>B</b> pathway regulators in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 11283-11288                          | 11.5 | 107       |
| 122 | International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 126, 25-36   | 5.3  | 105       |
| 121 | Comparison of Planning Quality and Efficiency Between Conventional and Knowledge-based Algorithms in Nasopharyngeal Cancer Patients Using Intensity Modulated Radiation Therapy.  International Journal of Radiation Oncology Biology Physics, 2016, 95, 981-990                       | 4    | 94        |

| 120 | The strength/weakness of the AJCC/UICC staging system (7th edition) for nasopharyngeal cancer and suggestions for future improvement. <i>Oral Oncology</i> , <b>2012</b> , 48, 1007-1013  | 4.4               | 93 |  |
|-----|---|-------------------|----|--|
| 119 | Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018777847                                    | 2.2               | 90 |  |
| 118 | Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy. <i>Cancer</i> , <b>2016</b> , 122, 3307-3315   | 6.4               | 88 |  |
| 117 | A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2011</b> , 98, 15-   | · <b>2½</b> ·3    | 86 |  |
| 116 | Major late toxicities after conformal radiotherapy for nasopharyngeal carcinoma-patient- and treatment-related risk factors. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 73, 112   | 21 <del>-</del> 8 | 80 |  |
| 115 | Management of locally recurrent nasopharyngeal carcinoma. Cancer Treatment Reviews, 2019, 79, 1018  | 904.4             | 78 |  |
| 114 | N-staging by magnetic resonance imaging for patients with nasopharyngeal carcinoma: pattern of nodal involvement by radiological levels. <i>Radiotherapy and Oncology</i> , <b>2007</b> , 82, 70-5  | 5.3               | 78 |  |
| 113 | Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 73, 1335-42   | 4                 | 76 |  |
| 112 | Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 204-10   | 5.3               | 74 |  |
| 111 | The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. <i>Oral Oncology</i> , <b>2014</b> , 50, 506-12   | 4.4               | 64 |  |
| 110 | Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2005</b> , 63, 133   | 31 <sup>4</sup> 8 | 63 |  |
| 109 | Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. <i>International Journal of Cancer</i> , <b>2015</b> , 136, E127-35  | 7.5               | 58 |  |
| 108 | Screening for family members of patients with nasopharyngeal carcinoma. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 998-1001  | 7.5               | 57 |  |
| 107 | Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review. <i>Oral Oncology</i> , <b>2016</b> , 53, 10-6   | 4.4               | 55 |  |
| 106 | Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. <i>Cancer Medicine</i> , <b>2015</b> , 4, 1079-90   | 4.8               | 52 |  |
| 105 | Therapeutic targeting of CBP/Ecatenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin. <i>Scientific Reports</i> , <b>2015</b> , 5, 9979  | 4.9               | 51 |  |
| 104 | A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. <i>Cancer</i> , <b>2017</b> , 123, 4147-4157 | 6.4               | 50 |  |
| 103 | International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2019</b> , 105, 567-580  | 4                 | 48 |  |

| 102 | Whole-exome sequencing identifies MST1R as a genetic susceptibility gene in nasopharyngeal carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 3317-22                                   | 11.5 | 45 |
|-----|---|------|----|
| 101 | A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. <i>Molecular Cancer</i> , <b>2013</b> , 12, 128   | 42.1 | 44 |
| 100 | Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 1004-10 | 4    | 44 |
| 99  | Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2006</b> , 28, 880-7                                 | 4.2  | 43 |
| 98  | Role of MIF/CXCL8/CXCR2 signaling in the growth of nasopharyngeal carcinoma tumor spheres. <i>Cancer Letters</i> , <b>2013</b> , 335, 81-92   | 9.9  | 42 |
| 97  | Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer. <i>Oral Oncology</i> , <b>2017</b> , 67, 52-60  | 4.4  | 37 |
| 96  | Nasopharyngeal carcinoma: salvage of local recurrence. <i>Oral Oncology</i> , <b>2012</b> , 48, 768-74  | 4.4  | 37 |
| 95  | Chemotherapy for Nasopharyngeal Carcinoma - Current Recommendation and Controversies.<br>Hematology/Oncology Clinics of North America, <b>2015</b> , 29, 1107-22  | 3.1  | 35 |
| 94  | Reirradiation with intensity-modulated radiotherapy for locally recurrent T3 to T4 nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2017</b> , 39, 533-540   | 4.2  | 34 |
| 93  | Staging of nasopharyngeal carcinomathe past, the present and the future. <i>Oral Oncology</i> , <b>2014</b> , 50, 549-54  | 4.4  | 34 |
| 92  | Clinical utility of plasma Epstein-Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 2720-9   | 6.4  | 34 |
| 91  | Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screening. <i>Familial Cancer</i> , <b>2009</b> , 8, 103-8  | 3    | 32 |
| 90  | Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,  | 9.7  | 31 |
| 89  | Parapharyngeal extension of nasopharyngeal carcinoma: still a significant factor in era of modern radiotherapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, 1082-9  | 4    | 31 |
| 88  | Quality of life in head and neck cancer survivors at 1 year after treatment: the mediating role of unmet supportive care needs. <i>Supportive Care in Cancer</i> , <b>2014</b> , 22, 2917-26  | 3.9  | 30 |
| 87  | Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. <i>Oral Oncology</i> , <b>2012</b> , 48, 162-7  | 4.4  | 30 |
| 86  | Outcomes of nasopharyngeal carcinoma screening for high risk family members in Hong Kong. <i>Familial Cancer</i> , <b>2010</b> , 9, 221-8   | 3    | 29 |
| 85  | Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer. <i>Head and Neck</i> , <b>2012</b> , 34, 1225-30   | 4.2  | 28 |

## (2011-2016)

| 84 | Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 78859-78871   | 3.3          | 28 |
|----|--|--------------|----|
| 83 | The prognostic value of histological typing in nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2012</b> , 48, 429-3  | <b>3</b> .4  | 26 |
| 82 | NF- <b>B</b> p65 Subunit Is Modulated by Latent Transforming Growth Factor-Binding Protein 2 (LTBP2) in Nasopharyngeal Carcinoma HONE1 and HK1 Cells. <i>PLoS ONE</i> , <b>2015</b> , 10, e0127239   | 3.7          | 26 |
| 81 | Predictive factors and radiological features of radiation-induced cranial nerve palsy in patients with nasopharyngeal carcinoma following radical radiotherapy. <i>Oral Oncology</i> , <b>2013</b> , 49, 49-54   | 4.4          | 26 |
| 8o | Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 100, 630-638 | 4            | 25 |
| 79 | Treatment of primary liver cancer using highly-conformal radiotherapy with kV-image guidance and respiratory control. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 102, 56-61  | 5.3          | 25 |
| 78 | Should all nasopharyngeal carcinoma with masticator space involvement be staged as T4?. <i>Oral Oncology</i> , <b>2014</b> , 50, 1188-95   | 4.4          | 24 |
| 77 | Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. <i>BMC Cancer</i> , <b>2011</b> , 11, 288  | 4.8          | 23 |
| 76 | Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region?. <i>American Journal of Infection Control</i> , <b>2016</b> , 44, 394-9   | 3.8          | 22 |
| 75 | Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 221  | 5.3          | 21 |
| 74 | Multigene pathway-based analyses identify nasopharyngeal carcinoma risk associations for cumulative adverse effects of TERT-CLPTM1L and DNA double-strand breaks repair. <i>International Journal of Cancer</i> , <b>2014</b> , 135, 1634-45                 | 7.5          | 20 |
| 73 | A Mixed-Methods Study of Unmet Supportive Care Needs Among Head and Neck Cancer Survivors. <i>Cancer Nursing</i> , <b>2019</b> , 42, 67-78   | 2.6          | 20 |
| 72 | Trends and patterns of breast conservation treatment in Hong Kong: 1994-2007. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2009</b> , 74, 98-103  | 4            | 19 |
| 71 | A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2012</b> , 48, 441-4   | 4.4          | 18 |
| 70 | Concurrent-Adjuvant Chemoradiation Therapy for Stage III-IVB Nasopharyngeal Carcinoma-Exploration for Achieving Optimal 10-Year Therapeutic Ratio. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 1078-1086         | 4            | 17 |
| 69 | If concurrentEdjuvant chemoradiotherapy is beneficial for locoregionally advanced nasopharyngeal carcinoma, would changing the sequence to inductionEoncurrent achieve better outcome?. <i>Journal of Radiation Oncology</i> , <b>2012</b> , 1, 107-115      | 0.7          | 17 |
| 68 | Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. <i>Gastric Cancer</i> , <b>2011</b> , 14, 63-   | <b>7/1</b> 6 | 17 |
| 67 | Can the analysis of ERCC1 expression contribute to individualized therapy in nasopharyngeal carcinoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 79, 1414-20   | 4            | 17 |

| 66 | Automatic segmentation for adaptive planning in nasopharyngeal carcinoma IMRT: Time, geometrical, and dosimetric analysis. <i>Medical Dosimetry</i> , <b>2020</b> , 45, 60-65  | 1.3  | 14 |
|----|--|------|----|
| 65 | Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant. <i>Current Treatment Options in Oncology</i> , <b>2015</b> , 16, 44   | 5.4  | 13 |
| 64 | NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma. <i>Cancer</i> , <b>2020</b> , 126, 3674-3688   | 6.4  | 13 |
| 63 | Crucifera sulforaphane (SFN) inhibits the growth of nasopharyngeal carcinoma through DNA methyltransferase 1 (DNMT1)/Wnt inhibitory factor 1 (WIF1) axis. <i>Phytomedicine</i> , <b>2019</b> , 63, 153058  | 6.5  | 13 |
| 62 | MicroRNA profiling study reveals miR-150 in association with metastasis in nasopharyngeal carcinoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 12012  | 4.9  | 12 |
| 61 | International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 682-695  | 4    | 11 |
| 60 | Current management of stage IV nasopharyngeal carcinoma without distant metastasis. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 85, 101995   | 14.4 | 10 |
| 59 | Patterns of care and treatment outcomes for local recurrence of NPC after definite IMRT-A study by the HKNPCSG. <i>Head and Neck</i> , <b>2019</b> , 41, 3661-3669   | 4.2  | 10 |
| 58 | IKBB tumor suppressive role in nasopharyngeal carcinoma via NF- <b>B</b> -mediated signalling. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 160-70  | 7.5  | 9  |
| 57 | A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 6002-6002 | 2.2  | 8  |
| 56 | Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 114-125  | 8.7  | 7  |
| 55 | Leukocyte telomere length associates with nasopharyngeal carcinoma risk and survival in Hong Kong Chinese. <i>International Journal of Cancer</i> , <b>2018</b> , 143, 2289-2298   | 7.5  | 7  |
| 54 | Translational research in nasopharyngeal carcinoma. <i>Oral Oncology</i> , <b>2014</b> , 50, 345-52  | 4.4  | 7  |
| 53 | An analysis of the efficacy of serial screening for familial nasopharyngeal carcinoma based on Markov chain models. <i>Familial Cancer</i> , <b>2011</b> , 10, 133-9   | 3    | 7  |
| 52 | Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 6523-6523   | 2.2  | 7  |
| 51 | Milk Consumption Across Life Periods in Relation to Lower Risk of Nasopharyngeal Carcinoma: A Multicentre Case-Control Study. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 253  | 5.3  | 6  |
| 50 | Test-retest reliability of a computer-assisted self-administered questionnaire on early life exposure in a nasopharyngeal carcinoma case-control study. <i>Scientific Reports</i> , <b>2018</b> , 8, 7052  | 4.9  | 6  |
| 49 | Perceived unmet supportive care needs and determinants of quality of life among head and neck cancer survivors: a research protocol. <i>Journal of Advanced Nursing</i> , <b>2013</b> , 69, 2750-8   | 3.1  | 6  |

## (2022-2020)

| 48 | Dose volume effects of re-irradiation for locally recurrent nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2020</b> , 42, 180-187   | 4.2   | 6 |
|----|--|-------|---|
| 47 | Head and neck cancer in Hong Kong. <i>Japanese Journal of Clinical Oncology</i> , <b>2018</b> , 48, 13-21  | 2.8   | 5 |
| 46 | Potential pitfalls in incorporating plasma Epstein-Barr virus DNA in the management of nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2020</b> , 42, 446-455  | 4.2   | 5 |
| 45 | Solar Ultraviolet Radiation and Vitamin D Deficiency on Epstein-Barr Virus Reactivation: Observational and Genetic Evidence From a Nasopharyngeal Carcinoma-Endemic Population. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa426 | 1     | 4 |
| 44 | Metastatic Squamous Cell Carcinoma to the Cervical Lymph Nodes From an Unknown Primary Cancer: Management in the HPV Era. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 593164  | 5.3   | 4 |
| 43 | Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG. <i>Oral Oncology</i> , <b>2020</b> , 111, 105012   | 4.4   | 4 |
| 42 | Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. <i>Communications Biology</i> , <b>2020</b> , 3, 759  | 6.7   | 4 |
| 41 | Cost minimization analysis of capecitabine versus 5-fluorouracil-based treatment for gastric cancer patients in Hong Kong. <i>Journal of Medical Economics</i> , <b>2017</b> , 20, 541-548   | 2.4   | 3 |
| 40 | Meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 4,798 patients <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6022-6022   | 2.2   | 3 |
| 39 | Treatment Outcomes of Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Series of 22 Patients and Treatment Strategy Review. <i>Hong Kong Journal of Radiology</i> , <b>2013</b> , 16, 270-277   | 0.1   | 3 |
| 38 | Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors. <i>Hong Kong Medical Journal</i> , <b>2017</b> , 23, 54-62                           | 0.7   | 3 |
| 37 | The International Atomic Energy Agency global initiatives on nasopharyngeal cancer treatment. <i>Chinese Clinical Oncology</i> , <b>2016</b> , 5, 27   | 2.3   | 3 |
| 36 | Limitation of radiological T3 subclassification of rectal cancer due to paucity of mesorectal fat in Chinese patients. <i>Hong Kong Medical Journal</i> , <b>2014</b> , 20, 366-70   | 0.7   | 3 |
| 35 | Radiotherapy in the management of glottic squamous cell carcinoma. <i>Head and Neck</i> , <b>2020</b> , 42, 3558-35  | 647.2 | 3 |
| 34 | Dietary fiber intake from fresh and preserved food and risk of nasopharyngeal carcinoma: observational evidence from a Chinese population. <i>Nutrition Journal</i> , <b>2021</b> , 20, 14   | 4.3   | 3 |
| 33 | A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. European Journal of Cancer, 2021, 153, 109-122  | 7.5   | 3 |
| 32 | A novel nomogram to predict overall survival in head and neck cancer survivors with radiation-induced brain necrosis <i>Radiotherapy and Oncology</i> , <b>2022</b> , 168, 121-129   | 5.3   | 2 |
| 31 | Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients <i>Clinical and Translational Radiation Oncology</i> , <b>2022</b> , 32, 59-68  | 4.6   | 2 |

| 30 | Prognostic and therapeutic evaluation of nasopharyngeal carcinoma by dynamic contrast-enhanced (DCE), diffusion-weighted (DW) magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS). <i>Magnetic Resonance Imaging</i> , <b>2021</b> , 83, 50-56                                      | 3.3   | 2 |
|----|--|-------|---|
| 29 | Advances in Radiotherapy <b>2019</b> , 263-288   |       | 1 |
| 28 | Salvage of Local Recurrence <b>2019</b> , 289-312  |       | 1 |
| 27 | Management of Nasopharyngeal Carcinoma in Elderly Patients Frontiers in Oncology, 2022, 12, 810690   | 5.3   | 1 |
| 26 | Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 6029-6029   | 2.2   | 1 |
| 25 | Proton/heavy ion therapy in salvage of locally recurrent nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , <b>2020</b> , 4, 4-4  | 0.3   | 1 |
| 24 | Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 111, 1227-1236 | 4     | 1 |
| 23 | Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 703995   | 5.3   | 1 |
| 22 | Maintenance Capecitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma-Magic Bullet or Pandora's Box?. <i>JAMA Oncology</i> , <b>2022</b> ,  | 13.4  | 1 |
| 21 | International Consensus on Delineation of Target Volumes and Organs at Risk <b>2019</b> , 239-261  |       | O |
| 20 | Application of Artificial Intelligence for Nasopharyngeal Carcinoma Management - A Systematic Review <i>Cancer Management and Research</i> , <b>2022</b> , 14, 339-366   | 3.6   | 0 |
| 19 | Dose-volume predictors of post-radiation primary hypothyroidism in head and neck cancer: A systematic review <i>Clinical and Translational Radiation Oncology</i> , <b>2022</b> , 33, 83-92  | 4.6   | О |
| 18 | Knowledge-based planning in nasopharyngeal carcinoma. <i>Annals of Nasopharynx Cancer</i> , <b>2020</b> , 4, 6-6   | 0.3   | O |
| 17 | Contemporary management of the neck in nasopharyngeal carcinoma. <i>Head and Neck</i> , <b>2021</b> , 43, 1949-19  | 9,6.3 | O |
| 16 | Dose-Response Reduction in Risk of Nasopharyngeal Carcinoma From Smoking Cessation: A Multicenter Case-Control Study in Hong Kong, China. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 699241  | 5.3   | О |
| 15 | Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges. <i>Cancers</i> , <b>2022</b> , 14, 2587   | 6.6   | O |
| 14 | Oligometastatic disease <b>2014</b> , 121-136  |       |   |
| 13 | Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7-year audit. <i>Surgical Practice</i> , <b>2010</b> , 14, 85-91  | 0.4   |   |

#### LIST OF PUBLICATIONS

2

Clinical Oncology Meeting, 2022, 42, 1-10

2022, 12, 842281

In Reply to Abbasi et al.. International Journal of Radiation Oncology Biology Physics, 2022, 112, 262-263 4 12 Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer. Current Opinion in 11 Otolaryngology and Head and Neck Surgery, 2021, 29, 86-92 Management of Nasopharyngeal Carcinoma 2016, 445-473 10 Nasopharynx. Medical Radiology, 2009, 57-73 0.2 9 Management of Nasopharyngeal Carcinoma 2011, 381-400 8 Standardization for oncologic head and neck surgery. European Archives of Oto-Rhino-Laryngology, 3.5 2021, 278, 4663-4669 Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. Lancet Oncology, The, 6 21.7 2021, 22, e217 Diagnosis and Staging of Nasopharyngeal Cancer. Practical Guides in Radiation Oncology, 2021, 1-21 Re-irradiation for recurrent NPCIs the treatment merited at all?. Annals of Nasopharynx Cancer, 0.3 2018, 1, 1-1 Low vitamin D exposure and risk of nasopharyngeal carcinoma: Observational and genetic evidence 5.9 from a multicenter case-control study. Clinical Nutrition, 2021, 40, 5180-5188 Disadvantaged Subgroups Within the Global Head and Neck Cancer Population: How Can We

Optimize Care?. American Society of Clinical Oncology Educational Book / ASCO American Society of

A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin.. *Frontiers in Oncology*,

7.1

5.3